202 related articles for article (PubMed ID: 8813040)
1. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
Saravolatz LD; Winslow DL; Collins G; Hodges JS; Pettinelli C; Stein DS; Markowitz N; Reves R; Loveless MO; Crane L; Thompson M; Abrams D
N Engl J Med; 1996 Oct; 335(15):1099-106. PubMed ID: 8813040
[TBL] [Abstract][Full Text] [Related]
2. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
Hammer SM; Katzenstein DA; Hughes MD; Gundacker H; Schooley RT; Haubrich RH; Henry WK; Lederman MM; Phair JP; Niu M; Hirsch MS; Merigan TC
N Engl J Med; 1996 Oct; 335(15):1081-90. PubMed ID: 8813038
[TBL] [Abstract][Full Text] [Related]
3. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
Abrams DI; Goldman AI; Launer C; Korvick JA; Neaton JD; Crane LR; Grodesky M; Wakefield S; Muth K; Kornegay S
N Engl J Med; 1994 Mar; 330(10):657-62. PubMed ID: 7906384
[TBL] [Abstract][Full Text] [Related]
4. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
Schooley RT; Ramirez-Ronda C; Lange JM; Cooper DA; Lavelle J; Lefkowitz L; Moore M; Larder BA; St Clair M; Mulder JW; McKinnis R; Pennington KN; Harrigan PR; Kinghorn I; Steel H; Rooney JF
J Infect Dis; 1996 Jun; 173(6):1354-66. PubMed ID: 8648207
[TBL] [Abstract][Full Text] [Related]
5. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Katzenstein DA; Hammer SM; Hughes MD; Gundacker H; Jackson JB; Fiscus S; Rasheed S; Elbeik T; Reichman R; Japour A; Merigan TC; Hirsch MS
N Engl J Med; 1996 Oct; 335(15):1091-8. PubMed ID: 8813039
[TBL] [Abstract][Full Text] [Related]
6. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
[TBL] [Abstract][Full Text] [Related]
7. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
Fischl MA; Stanley K; Collier AC; Arduino JM; Stein DS; Feinberg JE; Allan JD; Goldsmith JC; Powderly WG
Ann Intern Med; 1995 Jan; 122(1):24-32. PubMed ID: 7985892
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
Mauss S; Adams O; Willers R; Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(5):469-77. PubMed ID: 8605592
[TBL] [Abstract][Full Text] [Related]
9. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
Lancet; 1996 Aug; 348(9023):283-91. PubMed ID: 8709686
[TBL] [Abstract][Full Text] [Related]
10. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
[TBL] [Abstract][Full Text] [Related]
11. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.
Lancet; 1997 May; 349(9063):1413-21. PubMed ID: 9164314
[TBL] [Abstract][Full Text] [Related]
12. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
[TBL] [Abstract][Full Text] [Related]
13. Studies of zidovudine in combination with didanosine and zalcitabine.
Jablonowski H
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
[TBL] [Abstract][Full Text] [Related]
14. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
[TBL] [Abstract][Full Text] [Related]
15. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
Gatell JM; González-Lahoz J; Clotet B; Antunes F; Kasparova L; Gil-Aguado A; Saballs P; Santamaria JM; Podzamczer D; Miro JM; Jou A; Verdejo J; Doroana M; Thomis J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul; 12(3):249-58. PubMed ID: 8673528
[TBL] [Abstract][Full Text] [Related]
16. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group.
Graham NM; Hoover DR; Park LP; Stein DS; Phair JP; Mellors JW; Detels R; Saah AJ
Ann Intern Med; 1996 Jun; 124(12):1031-8. PubMed ID: 8633816
[TBL] [Abstract][Full Text] [Related]
17. Treatment options in zidovudine intolerance or failure.
Abrams DI
AIDS; 1994 Sep; 8 Suppl 3():S3-7. PubMed ID: 7840914
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]